Tevogen Bio Inc (“Tevogen Bio”) announces the inception of Tevogen.ai, a new initiative focused on harnessing the potential of artificial intelligence (AI) for the enhancement of drug discovery, development, manufacturing, distribution, and patient access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231010880299/en/
Tevogen.ai will bring together a dedicated team of research scientists, physicians, data scientists, and AI/machine learning (ML) engineers committed to the ethical development and commercialization of AI-driven and AI-enhanced tools designed to streamline processes and improve health outcomes.
“The launch of Tevogen.ai signifies more than just the inception of a new initiative. It is a testament to our vision of pushing the boundaries of what is achievable in medicine. Through the combination of our biotech expertise and AI’s capabilities, we believe we are setting the stage for significant advancements in healthcare,” stated Ryan Saadi, MD, MPH, CEO of Tevogen Bio.
About Tevogen Bio
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.
Forward Looking Statements
This press release contains certain forward-looking statements relating to the Tevogen Bio and its business, including without limitation statements regarding Tevogen Bio’s plans for and the potential benefits of Tevogen.ai and the product candidates, products, markets, and expected future performance and market opportunities of Tevogen Bio. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to several factors which involve known and unknown risks, delays, uncertainties, and other factors not under Tevogen Bio’s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “believe,” “potential,” and “possible,” or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which Tevogen Bio expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between Tevogen Bio’s expectations and actual results, including, among others: changes in the markets in which Tevogen Bio competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen Bio may not be able to execute its growth strategies; Tevogen Bio’s limited operating history; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review and approval and commercial development; risks associated with intellectual property protection; and other risks related to matters that could affect Tevogen Bio’s future financial results, including the commercial potential, sales, and pricing of Tevogen Bio’s products. Except as required by law, Tevogen Bio undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions therefrom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231010880299/en/
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
